Where Tech Meets Bio | BiopharmaTrend | Substack

Weekly Tech+Bio #80: Organoids on Artemis II

Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree

Apr 6 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

Everyone is Launching AI Agents. What's Being Deployed?

A check-in on biopharma's agentic AI buildout

Apr 4 • Roman Kasianov and Andrii Buvailo, PhD

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg

Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science

Mar 30 • Roman Kasianov and Andrii Buvailo, PhD

Weekly Tech+Bio Highlights #78: AI Agents Rush In

Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, and agents are everywhere

Mar 23 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

Weekly Tech+Bio Highlights #77: AI-Guided mRNA Vaccine Shrinks Dog's Cancer

Google's AI doctor passes its first clinic test, China's first take-home BCI, OpenFold3 goes fully open, and arXiv is going independent

Mar 16 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD

Most Popular

Cancer as a Data Problem: What AI Is Doing in Oncology

Feb 27 • BiopharmaTrend

Five Genomics Watchpoints for 2026

Feb 20 • BiopharmaTrend

2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Jan 15 • BiopharmaTrend

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Mar 7 • BiopharmaTrend

Join 11k+ biotech industry professionals tracking strategy signals in the 'techbio' space

Features

On Predicting Probability of Technical and Regulatory Success With AI

Insights from The American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Nov 7, 2024 • BiopharmaTrend

Using AI to Predict the Probability of Success in Drug Development

ALSO: Patented AI Platform Identifies Promising Early-Stage Biopharma Assets and Companies

Jun 13, 2024

Building Data Infrastructure for Biology

ALSO: Featuring Omics Solution Providers Market Map, from Multiomics to Spatial Biology

May 23, 2024

49:15

Enabling Precision Medicine with AI

A Deep Dive with Lantern Pharma's CEO, Panna Sharma

Mar 7, 2024 • Andrii Buvailo, PhD

Deep Dives

Everyone is Launching AI Agents. What's Being Deployed?

A check-in on biopharma's agentic AI buildout

Apr 4 • Roman Kasianov and Andrii Buvailo, PhD

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.

Mar 14 • BiopharmaTrend

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.

Mar 7 • BiopharmaTrend

Cancer as a Data Problem: What AI Is Doing in Oncology

We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to…

Feb 27 • BiopharmaTrend

Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one…

Feb 20 • BiopharmaTrend

Recommendations

Michael Spencer

Special Competitive Studies Project

SCSP

Molecules & Empires

Andrii Buvailo, PhD

The Connected Ideas Project

Alexander Titus

Forever.AI: AI, Robotics, Quantum, Longevity, Cryonics & BCI

Alex Zhavoronkov

Recent posts

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.

Mar 14 • BiopharmaTrend

Weekly Tech+Bio Highlights #76: Neurons, Genomes, and Self-Driving Labs

Living neurons play DOOM, Lilly uses digital twins to scale GLP-1 production, generative genomics are now in Nature, and a rice-grain-sized retinal…

Mar 9 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.

Mar 7 • BiopharmaTrend

Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey

Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic…

Mar 2 • BiopharmaTrend and Roman Kasianov

The latest from

Andrii Buvailo, PhD

Weekly Tech+Bio #80: Organoids on Artemis II

Roman Kasianov

Weekly Tech+Bio #80: Organoids on Artemis II

BiopharmaTrend

Weekly Tech+Bio #80: Organoids on Artemis II

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts